Verition Fund Management
GALT icon

Verition Fund Management’s Galectin Therapeutics GALT Stock Holding History

Verition Fund Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,808
Closed -$76K – 1179
2019
Q1 		$76K Buy
+14,808
New +$71.1K ﹤0.01% 1034
2018
Q2 		– Sell
-10,195
Closed -$48K – 1166
2018
Q1 		$48K Buy
+10,195
New +$47.5K ﹤0.01% 1077

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Verition Fund Management's GALT Position: Q2 2019 in Review

Verition Fund Management sold out of Galectin Therapeutics (GALT) in Q2 2019, closing a stake of 14,808 shares — an estimated $76K sold.

Verition Fund Management first reported a position in GALT in Q1 2018 and held it in 2 quarters. The position peaked at $76K in Q1 2019. 76 funds tracked by Wall St. Rank hold GALT as of Q2 2019.

  • Verition Fund Management reported no remaining Galectin Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Verition Fund Management sold 14,808 Galectin Therapeutics shares in Q2 2019, an estimated $76K.
  • Verition Fund Management first reported a position in Galectin Therapeutics in Q1 2018 and held it in 2 quarters.
  • Verition Fund Management's Galectin Therapeutics position peaked at $76K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2019.

Based on Verition Fund Management's 13F filing for Q2 2019, filed 14 Aug 2019.